EA200602200A1 - Меркаптоимидазолы в качестве антагонистов рецепторов ccr2 - Google Patents

Меркаптоимидазолы в качестве антагонистов рецепторов ccr2

Info

Publication number
EA200602200A1
EA200602200A1 EA200602200A EA200602200A EA200602200A1 EA 200602200 A1 EA200602200 A1 EA 200602200A1 EA 200602200 A EA200602200 A EA 200602200A EA 200602200 A EA200602200 A EA 200602200A EA 200602200 A1 EA200602200 A1 EA 200602200A1
Authority
EA
Eurasian Patent Office
Prior art keywords
6alkyl
nrr
hydrogen
antagonists
cyano
Prior art date
Application number
EA200602200A
Other languages
English (en)
Other versions
EA010974B1 (ru
Inventor
Густаф Мария Букс
Ги Розалия Эген Ван Ломмен
Жюльен Жорж Пьер-Оливье Дойон
Эрвин Кусеманс
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200602200A1 publication Critical patent/EA200602200A1/ru
Publication of EA010974B1 publication Critical patent/EA010974B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Настоящее изобретение относится к соединению формулы (I)его N-оксиду, его фармацевтически приемлемой аддитивной соли, его четвертичному амину или стереохимически изомерной форме, где Rпредставляет собой водород, Cалкил, Сциклоалкил, СалкилоксиСалкил, ди(Cалкил)аминоСалкил, арил или гетероарил; каждый Rнезависимо представляет собой галоген, Cалкил, Cалкилокси, Cалкилтио, полигалогенСалкил, полигалогенСалкилокси, циано, аминокарбонил, амино, моно- или ди(Cалкил)амино, нитро, арил или арилокси; Rпредставляет собой водород, циано, необязательно замещенный Cалкил, C(=O)-O-R, C(=O)-NRR, C(=S)-NRR, S(=O)-NRRили C(=O)-R; Rпредставляет собой водород или Cалкил; n равно 1, 2, 3, 4 или 5; Z представляет собой циклическую структуру. Кроме того, данное изобретение относится к способу получения соединений формулы (I), их использованию в качестве антагонистов CCR2 и фармацевтическим композициям, их содержащим.
EA200602200A 2004-05-26 2005-05-24 Меркаптоимидазолы в качестве антагонистов рецепторов ccr2 EA010974B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2004050935 2004-05-26
PCT/EP2005/052373 WO2005118574A1 (en) 2004-05-26 2005-05-24 Mercaptoimidazoles as ccr2 receptor antagonists

Publications (2)

Publication Number Publication Date
EA200602200A1 true EA200602200A1 (ru) 2007-04-27
EA010974B1 EA010974B1 (ru) 2008-12-30

Family

ID=34957673

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200602200A EA010974B1 (ru) 2004-05-26 2005-05-24 Меркаптоимидазолы в качестве антагонистов рецепторов ccr2

Country Status (14)

Country Link
US (1) US20070244138A1 (ru)
EP (1) EP1756089B1 (ru)
JP (1) JP2008500311A (ru)
CN (1) CN1956976A (ru)
AR (1) AR049119A1 (ru)
AT (1) ATE411989T1 (ru)
AU (1) AU2005250157A1 (ru)
CA (1) CA2565280A1 (ru)
DE (1) DE602005010577D1 (ru)
EA (1) EA010974B1 (ru)
ES (1) ES2317247T3 (ru)
MY (1) MY139783A (ru)
TW (1) TW200606155A (ru)
WO (1) WO2005118574A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8471004B2 (en) * 2009-10-07 2013-06-25 Hoffman-La Roche Inc. Bicyclic compounds
US20140329809A1 (en) 2011-10-28 2014-11-06 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
WO2016010610A2 (en) * 2014-07-18 2016-01-21 Ohio University Imidazole and thiazole compositions for modifying biological signaling

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1487326A (fr) 1966-01-18 1967-07-07 Clin Byla Ets Dérivés imidazoliques et leur préparation
JPS5343958B2 (ru) * 1972-07-29 1978-11-24
EP0277384A3 (en) 1986-12-24 1990-05-23 Janssen Pharmaceutica N.V. 1h-imidazole-5-carboxylic acid derivatives
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US6040320A (en) * 1997-06-30 2000-03-21 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
JP3573925B2 (ja) * 1997-08-28 2004-10-06 三洋電機株式会社 金属−水素化物アルカリ蓄電池及びその製造方法
DE10107683A1 (de) 2001-02-19 2002-08-29 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
US20050004180A1 (en) * 2001-10-03 2005-01-06 ZOU Dong Pyrrolidinone derivatives
DE10222103A1 (de) 2002-05-17 2003-11-27 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
WO2004069809A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7547717B2 (en) * 2004-03-08 2009-06-16 Wyeth Ion channel modulators
WO2005118578A1 (en) * 2004-05-26 2005-12-15 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
CA2573066A1 (en) * 2004-08-11 2006-02-16 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists

Also Published As

Publication number Publication date
AU2005250157A1 (en) 2005-12-15
EP1756089A1 (en) 2007-02-28
DE602005010577D1 (de) 2008-12-04
AR049119A1 (es) 2006-06-28
TW200606155A (en) 2006-02-16
ATE411989T1 (de) 2008-11-15
MY139783A (en) 2009-10-30
WO2005118574A1 (en) 2005-12-15
JP2008500311A (ja) 2008-01-10
EA010974B1 (ru) 2008-12-30
US20070244138A1 (en) 2007-10-18
CA2565280A1 (en) 2005-12-15
EP1756089B1 (en) 2008-10-22
CN1956976A (zh) 2007-05-02
ES2317247T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
EA200970171A1 (ru) Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
MY139335A (en) Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists
DK165365C (da) Analogifremgangsmaade til fremstilling af n-(3-hydroxy-4-piperidinyl)benzamidderivater
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
EA200901379A1 (ru) Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
MXPA03010129A (es) N-aroilaminas-ciclicas.
EA200501326A1 (ru) Пиримидины и триазины, ингибирующие репликацию вич
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
SE0400284D0 (sv) Novel compounds
RU2015102333A (ru) Жидкие препараты аминов и органических кислот, стабилизированные солями
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
ATE399770T1 (de) Tachykininrezeptorantagonisten
EA200300718A1 (ru) Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
AR064136A1 (es) Derivados de espiro-piperidina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas con la accion antagonista del receptor v1a.
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
SE0201194D0 (sv) New compounds
EA200602200A1 (ru) Меркаптоимидазолы в качестве антагонистов рецепторов ccr2
EA200602193A1 (ru) Меркаптоимидазолы в качестве антагонистов рецептора ccr2
EA200970364A1 (ru) Новые производные имидазолонов в качестве лекарственных средств, способ их получения, фармацевтические композиции и применение в качестве ингибиторов протеинкиназ, в частности, cdc7

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU